B. Zussman

发表

Paroxetine does not affect the cardiac safety and pharmacokinetics of terfenadine in healthy adult men.

D. Jorkasky, L. Benincosa, D. Martin, 1997, Journal of clinical psychopharmacology.

Pharmacokinetics of Rosiglitazone in Patients with End-Stage Renal Disease

M. Freed, B. Zussman, K. Thompson-Culkin, 2002, The Journal of international medical research.

Linear Pharmacokinetic Behavior of Ropinirole during Multiple Dosing in Patients with Parkinson's Disease

J. Hubble, W. Koller, A. Taylor, 2000, Journal of clinical pharmacology.

The pharmacokinetics of paroxetine in the elderly

E. A. Allen, M. Byrne, A. Bayer, 1989, Acta psychiatrica Scandinavica. Supplementum.

The relationship between paroxetine and the sparteine oxidation polymorphism

J. Hallas, E. Skjelbo, K. Brøsen, 1992, Clinical pharmacology and therapeutics.

Paroxetine plasma levels: lack of correlation with efficacy or adverse events

C. Bye, T. Tasker, B. Zussman, 1989, Acta psychiatrica Scandinavica. Supplementum.

The pharmacokinetics of paroxetine in renal impairment

M. Byrne, M. Laher, J. Kelly, 1989, Acta psychiatrica Scandinavica. Supplementum.

Pharmacokinetics and tolerability of ascending intravenous doses of granisetron, a novel 5-HT3 antagonist, in healthy human subjects

J. Upward, D. Pierce, B. Zussman, 2004, European Journal of Clinical Pharmacology.

Lack of Pharmacokinetic Interactions Between Cilomilast and Theophylline or Smoking in Healthy Volunteers

R. Murdoch, B. Zussman, D. Webber, 2004, Journal of clinical pharmacology.

A pharmacokinetic study of granisetron (BRL 43694A), a selective 5-HT3 receptor antagonist: correlation with anti-emetic response

A. Harris, W. Rapeport, B. Cantwell, 2004, Cancer Chemotherapy and Pharmacology.

Pharmacokinetics and anti-emetic efficacy of BRL43694, a new selective 5HT-3 antagonist.

W. Rapeport, S. Kaye, J. Cassidy, 1988, British Journal of Cancer.

An Overview of the Pharmacokinetics of Cilomilast (Ariflo®), a New, Orally Active Phosphodiesterase 4 Inhibitor, in Healthy Young and Elderly Volunteers

J. Upward, A. Port, P. Wyld, 2001, Journal of clinical pharmacology.

Bioavailability of the Oral Selective Phosphodiesterase 4 Inhibitor Cilomilast

J. Kelly, R. Murdoch, B. Zussman, 2001, Pharmacotherapy.

A review of the metabolism and pharmacokinetics of paroxetine in man

C. Kaye, R. Haddock, P. Langley, 1989, Acta psychiatrica Scandinavica. Supplementum.

Cilomilast: pharmacokinetic and pharmacodynamic interactions with digoxin.

C. Schubert, J. Kelly, R. Murdoch, 2001, Clinical therapeutics.

Determination of paroxetine in human plasma, using high-performance liquid chromatography with fluorescence detection.

M. Brett, B. Zussman, P. Coates, 1987, Journal of chromatography.